IMPORTANCE Serum calcium has been associated with cardiovascular disease in observational studies and evidence from randomized clinical trials indicates that calcium supplementation, which raises serum calcium levels, may increase the risk of cardiovascular events, particularly myocardial infarction.
C alcium has a vital role in many biological processes in the body such as nerve transmission, blood clotting, blood pressure regulation, enzyme activation, hormone regulation, and muscle contraction. Observational studies have suggested that serum calcium levels are positively associated with risk of cardiovascular disease, including myocardial infarction. 1, 2 Moreover, evidence from randomized clinical trials indicates that calcium supplementation, which results in an acute and sustained elevation in serum calcium, 3,4 may modestly increase the risk of cardiovascular events, particularly myocardial infarction. 5 However, it remains unclear whether lifelong elevated serum calcium may be causally associated with coronary artery disease (CAD) risk. Nationally representative data show that one-fifth of US adults use calcium supplements, 6 and the proportion is even higher among middle-aged and older women and individuals with disabilities, with more than half of this group being regular calcium supplement users. [7] [8] [9] Because of the widespread use of calcium supplements, any association between raised serum calcium and CAD risk by a high calcium intake could have clinical and public health implications. The findings of an elevated risk of cardiovascular events with calcium supplement use 5 have been debated in recent years without consensus being reached.
10-12
Genetic variants that have a specific influence on possible risk factors can be used to assess associations with explicit outcomes. 13 This method, known as mendelian randomization, avoids some of the limitations of observational studies (because genetic information should be free from confounding) and is not affected by disease status, thereby avoiding reverse causation bias. 13 Hence, genetic variants that influence serum calcium levels could serve as instrumental variables (proxies) to determine the association of lifelong elevated serum calcium with CAD risk. We conducted a mendelian randomization study to investigate the association of serum calcium with CAD and myocardial infarction.
Methods

Study Design and Data Sources
The mendelian randomization approach builds upon 3 principal assumptions ( Figure 1) . 15 First, the genetic variants utilized as instrumental variables should be associated with the risk factor. Second, the genetic variants should not be associated with confounders. Third, the genetic variants should affect the risk of the outcome through the risk factor, not via other pathways. This study involved analysis of publicly available, deidentified data; specific ethical review and informed consent had been obtained in all of the original studies. This mendelian randomization study was designed to use summary statistics from large-scale genome-wide association studies (GWAS) (Figure 2) . GWAS identified 7 singlenucleotide polymorphisms (SNPs) associated with serum calcium levels in a meta-analysis of 39 400 individuals of European ancestry and which were replicated in up to 21 679 additional individuals (up to 61 079 individuals). (Figure 2 ). Of the 7 SNPs associated with serum calcium, 1 variant (rs780094 in the GCKR gene region) had pleiotropic associations at the Bonferronicorrected significance threshold ([P < .05]/7 SNPs = .007) with lipids, glycemic traits, type 2 diabetes, and measures of adiposity (eTable in the Supplement). To avoid violations of the mendelian randomization assumptions (Figure 1 ), the pleiotropic SNP was omitted. Thus, 6 SNPs associated with serum calcium were used as instrumental variables in the mendelian randomization analyses. Summary statistics for the associations of the 6 remaining calcium-associated SNPs with the prespecified primary outcomes of CAD and myocardial infarction were extracted from the Coronary Artery Disease Genome-Wide Replication and Meta-analysis plus the Coronary Artery Disease Genetics (CardiogramplusC4D) consortium's 1000 genomes-based genome-wide association meta-analysis of 48 studies.
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Case status was determined using a broad definition of CAD, including myocardial infarction (approximately 70% of the total number of cases), acute coronary syndrome, chronic stable angina, or coronary artery stenosis greater than 50% ( Table 1) .
Key Points
Question Are genetically elevated serum calcium levels associated with an increased risk of coronary artery disease or myocardial infarction?
Findings In this mendelian randomization study including 60 801 cases of coronary artery disease and 123 504 noncases, genetically elevated serum calcium levels were associated with increased odds of coronary artery disease and myocardial infarction (odds ratio per 0.5-mg/dL increase in genetically predicted serum calcium levels, 1.25 and 1.24, respectively).
Meaning A genetic predisposition to higher serum calcium levels was associated with increased risk of coronary artery disease and myocardial infarction.
Statistical Analysis
SNPs were matched across the data sources by assigning them to the same effect allele. The association of each SNP with CAD and myocardial infarction was weighted by its association with serum calcium, and estimates were combined using an inverse-variance weighted meta-analysis. 24 Complementary analyses using the weighted median and MR-Egger regression methods were performed. 24 The odds ratios (ORs) of CAD and myocardial infarction were scaled per 0.5-mg/dL increase (about 1 SD) in serum calcium levels. For the calcium-associated SNPs, the summary statistics were based on 44 to all 48 studies included in the CardiogramplusC4D consortium. All statistical tests were 2-sided. 
Results
The analytic sample included up to 60 801 CAD cases (approximately 70% with myocardial infarction) and 123 504 noncases from 48 cohort and case-control studies. The majority of participants were of European (77%), South Asian (13%), and East Asian (6%) ancestry ( Table 1) . The 6 SNPs related to serum calcium levels and without pleiotropic associations with potential confounders were estimated to explain about 0.8% of the variation in serum calcium levels. None of the individual 6 SNPs was associated with CAD at Bonferroni corrected significance level (P < .008) ( Table 2 ). In the overall inverse-variance weighted metaanalysis of the 6 SNPs, the OR of CAD per 0.5-mg/dL increase (about 1 SD) in genetically predicted serum calcium was 1.25 (95% CI, 1.08-1.45; P = .003) (Figure 3) . In a sensitivity analysis excluding the SNP in the CASR gene, which provided the most weight to the overall estimate, the OR of CAD was 1.25 (95% CI, 0.97-1.62). An analysis of patients with only myocardial infarction as the outcome (about 70% of all study cases) yielded similar results (OR, 1.24 [95% CI, 1.05-1.46]; P = .009) (eFigure in the Supplement).
The association between genetically predicted serum calcium levels and CAD was consistent in complementary analyses using the weighted median method (OR, 1. 
Discussion
This mendelian randomization study showed that a genetic predisposition to higher serum calcium levels was associated with increased risk of CAD and myocardial infarction. The OR per 0.5-mg/dL increase (about 1 SD) in serum calcium levels was 1.25 for CAD and 1.24 for myocardial infarction. The risk increase is similar or weaker in magnitude to previously reported genetic associations (per 1-SD increase) with triglyceride levels (OR, The finding from this study corroborates results from several observational studies showing a positive association of serum calcium levels with risk of cardiovascular disease. 1, 2 A meta-analysis of 8 observational studies found a hazard ratio of cardiovascular disease of 1.08 (95% CI, 1.04-1.13) per 1-SD increment of serum calcium levels and a corresponding OR of 1.22 (95% CI, 1.11-1.32) in 2 studies that reported ORs. (8) 2938 (51) 50 (8) History of MI or coronary revascularization
Abbreviations: CAD, coronary artery disease; CHD, coronary heart disease; ECG, electrocardiogram/electrocardiography;
ICD-10, International Classification of Diseases, 10th Revision; MI, myocardial infarction; NA, not available. as well as an increased risk of myocardial infarction. 5 Based on results from interventions, there is a peak in ionized and total serum calcium levels 4 hours after ingestion of 1000-mg supplemental calcium and the increase in total serum calcium corresponds to about 1 SD.
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A similar increase in serum calcium from baseline over 6 hours is observed following the ingestion of a 500-mg calcium supplement, whereas the increase in serum calcium after a corresponding calcium dose by a dairy product intake is less pronounced. 29 In a meta-analysis of 9 randomized clinical trials, calcium supplementation with or without vitamin D increased the risk of myocardial infarction by 24%, 5 but the result is disputed.
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Findings from observational studies further show that calcium supplement use is associated with increased risk of incident coronary artery calcification, 30 incident myocardial infarction, 31 and coronary heart disease mortality. 32 Possible mechanisms whereby elevated serum calcium levels may increase the risk of CAD include effects on vascular calcification, vascular cells, blood coagulation, and altered gene expression induced by effects on arterial wall calcium-sensing receptor. 10 The potential mechanisms underlying the association need to be more thoroughly evaluated. Strengths of this mendelian randomization analysis include the large sample size and the use of multiple uncorre- 
Limitations
This study has several limitations. First, the genetic variant in the CASR gene provided more weight, explained by the stronger relation between this SNP and serum calcium, than the other variants to the overall estimate of the genetic association between serum calcium levels and CAD. However, 4 of the other 5 variants associated with serum calcium had positive estimates for association with CAD, and 3 variants had higher ORs for association with CAD per 0.5 mg/dL increase in serum calcium compared with the genetic variant in the CASR gene. Moreover, the overall estimate was identical although with lower precision after omitting the variant in CASR. CASR encodes the calcium-sensing receptor, which plays a key role in calcium homeostasis. Second, there was partial overlap between studies included in the GWAS meta-analysis of calcium (N = 61 069) and the CardiogramplusC4D consortium (N = 184 305). This could result in model overfitting if the SNP-calcium associations were estimated in studies that were included in the CardiogramplusC4D consortium. Of the 28 studies included in the GWAS meta-analysis of calcium, 9 were also included in CardiogramplusC4D. If all the individuals in each of these studies appeared in both meta-analyses, then there would be an overlap of 26 776 of the 61 069 individuals in the calcium GWAS meta-analysis. This could potentially lead to a small bias in mendelian randomization estimates. However, if genetic associations with serum calcium levels were estimated in noncases only (as is usual for continuous phenotypes such as serum calcium levels), then this sample overlap would not lead to bias or type 1 error inflation. 33 Third, the study lacked complete information on sex and age, and that a potential nonlinear association between serum calcium levels and CAD could not be evaluated.
Fourth, a replication data set with a similar large number of CAD cases was not available.
The reliability of the findings from a mendelian randomization study depends on 3 key assumptions (Figure 1 ), which could be violated by population stratification, canalization, pleiotropy, and linkage disequilibrium. It cannot be completely ruled out that population stratification may have had some influence on the results because the CardiogramplusC4D consortium included individuals of different ancestry with potentially different allele frequencies. However, analyses for the CardiogramplusC4D consortium were conducted separately in each study and then combined, and adjustment was made for genetic principal components, mitigating the potential effect of population stratification.
Furthermore, the vast majority of participants in CardiogramplusC4D were of European descent and the effect allele frequencies of the 6 calcium-associated SNPs were very similar in CardiogramplusC4D and the GWAS meta-analysis of calcium. The SNP in the CASR gene has been consistently associated with serum calcium in populations of different ancestry, including Europeans, Indian Asians, and Japanese. 16, 34 The other 5 SNPs were robustly associated with serum calcium in a GWAS meta-analysis of about 61 000 individuals. 16 Whether canalization, which is defined as compensatory feedback mechanisms, may have affected the results could not be directly tested. Because canalization assumes that there are other mechanisms that mitigate the genetic effect, such feedback mechanisms would bias the results toward the null and cannot explain the observed association.
Several approaches were undertaken to assess and adjust for potential confounding or pleiotropic effects. First, each SNP associated with serum calcium was assessed for associations with known cardiometabolic risk factors for CAD, and 1 SNP with pleiotropic associations was excluded. In addition, sensitivity analyses using the weighted median and MR-Egger regression approaches to explore and adjust for pleiotropy were conducted. The results were consistent in these analyses, indicating that confounding is unlikely to explain the observed association. Linkage disequilibrium with directly causal variants (violating the third assumption) was likely avoided owing to the use of multiple SNPs of which most were positively associated with CAD.
Conclusions
A genetic predisposition to higher serum calcium levels was associated with increased risk of CAD and myocardial infarction. Whether the risk of CAD associated with lifelong genetic exposure to increased serum calcium levels can be translated to a risk associated with short-term to medium-term calcium supplementation is unknown. ). BMI, body mass index; DBP, diastolic blood pressure; DIAGRAM, Diabetes Genetics Replication and Meta-analysis; FG, fasting glucose; FI, fasting insulin; GIANT, Genetic Investigation of Anthropometric Traits; GLGC, Global Lipids Genetics Consortium; HDL-C, high-density lipoprotein cholesterol; ICBP, International Consortium of Blood Pressure Genome-Wide Association Studies; LDL-C, low-density lipoprotein cholesterol; MAGIC, Meta-Analyses of Glucose and Insulin-related traits Consortium; SNP, single-nucleotide polymorphism; SBP, systolic blood pressure; T2D, type 2 diabetes; TGs, triglycerides; Total-C, total cholesterol; WHR aBMI, waist-to-hip ratio adjusted for body mass index. *This SNP was excluded from the analyses because of pleiotropic associations with cardiometabolic traits. eFigure 1. Mendelian Randomization Estimates of the Association Between Genetically Predicted Serum Calcium Levels and Myocardial Infarction a CI, confidence interval; EA, effect allele; NEA, non-effect allele; OR, odds ratio; SNP, single-nucleotide polymorphism. a Odds ratios are per 0.5 mg/dL (about 1-SD) increase in genetically predicted serum calcium levels. Squares indicate the OR for the association of each calcium-associated SNP with myocardial infarction (size of the square is inversely proportional to variance of the estimate); horizontal lines indicate 95 CIs; diamond indicates the overall OR estimate with its 95% CI.
